⌘K
t
| Date | 22 Nov 2022 |
| Time | 07:00:10 |
| Category | Miscellaneous |
| ID | 1231H |
ECO Animal Health Group plc
(''ECO" or the "Group") (AIM: EAH)
Investor Presentation covering Interim Results
ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the Group's interim results for the period ended 30 September 2022.
The online presentation will take place on Monday 28 November at 10.00 am UK time. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.
To register for the event, please click here
A video recording of the presentation will be available shortly afterwards here
Contacts:
|
ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
|
|
|
IFC Advisory Graham Herring Zach Cohen
|
020 3934 6630
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas
|
020 7496 3000 |
|
Investec (Joint Broker) Gary Clarence Daniel Adams Carlo Spingardi
|
020 7597 5970 |
|
Peel Hunt LLP (Joint Broker) Dr Christopher Golden James Steel
|
020 7418 8900 |
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products